Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
PTC Therapeutics revenue
PTC Therapeutics's revenue is $806.8 million.
What is PTC Therapeutics's revenue?
- PTC Therapeutics's revenue growth from 2012 to 2024 is 2,276.66%.
- PTC Therapeutics has 517 employees, and the revenue per employee ratio is $1,560,502.
- PTC Therapeutics's peak quarterly revenue was $307.1M in 2023(q4).
- PTC Therapeutics peak revenue was $937.8M in 2023.
- PTC Therapeutics annual revenue for 2023 was 937.8M, 34.2% growth from 2022.
- PTC Therapeutics annual revenue for 2024 was 806.8M, -13.97% growth from 2023.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
PTC Therapeutics historical revenue
PTC Therapeutics's peak revenue was $937.8M in 2023. The peak quarterly revenue was $307.1M in 2023(q4).
PTC Therapeutics's revenue increased from $33.9m in 2012 to $806.8M currently. That's a 2,276.66% change in annual revenue.
PTC Therapeutics annual revenue
PTC Therapeutics annual revenue over time
| Fiscal year / year | PTC Therapeutics revenue |
|---|---|
| 2012 | $33.9M |
| 2013 | $34.7M |
| 2014 | $25.2M |
| 2015 | $36.8M |
| 2016 | $82.7M |
| 2017 | $194.4M |
| 2018 | $264.7M |
| 2019 | $307.0M |
| 2020 | $380.8M |
| 2021 | $538.6M |
| 2022 | $698.8M |
| 2023 | $937.8M |
| 2024 | $806.8M |
How accurately did PTC Therapeutics' revenue projections match actual performance?
PTC Therapeutics annual growth
PTC Therapeutics saw the greatest revenue growth in 2017, when revenue increased by 135.04%.
PTC Therapeutics had the lowest revenue growth in 2014, when revenue changed by -27.24%.
PTC Therapeutics annual growth rate over time
| Year | PTC Therapeutics growth |
|---|---|
| 2013 | 2%↑ |
| 2014 | -27%↓ |
| 2015 | 46%↑ |
| 2016 | 125%↑ |
| 2017 | 135%↑ |
| 2018 | 36%↑ |
| 2019 | 16%↑ |
| 2020 | 24%↑ |
| 2021 | 41%↑ |
| 2022 | 30%↑ |
| 2023 | 34%↑ |
| 2024 | -14%↓ |
PTC Therapeutics quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
PTC Therapeutics quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2013 | - | $5.9M | $15.5M | $7.3M |
| 2014 | $9.2M | $1.4M | $798,927 | $13.9M |
| 2015 | $7.5M | $6.8M | $9.8M | $12.7M |
| 2016 | $18.9M | $15.6M | $23.0M | $25.2M |
| 2017 | $26.5M | $48.0M | $41.9M | $78.0M |
| 2018 | $56.1M | $68.7M | $53.6M | $86.3M |
| 2019 | $53.6M | $85.5M | $71.4M | $96.5M |
| 2020 | $68.3M | $75.2M | $118.4M | $118.9M |
| 2021 | $117.9M | $116.7M | $138.7M | $165.2M |
| 2022 | $148.7M | $165.5M | $217.1M | $167.4M |
| 2023 | $220.4M | $213.8M | $196.6M | $307.1M |
| 2024 | $210.1M | $186.7M | $196.8M | $213.2M |
PTC Therapeutics jobs nearby
Do you work at PTC Therapeutics?
Is PTC Therapeutics transparent about its revenue structure?
PTC Therapeutics financial information
| CEO | Stuart W. Peltz Ph.d |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 517 |
| Date Founded | 1998 |
| Headquarters | South Plainfield, New Jersey |
| Number of Locations | 7 |
| Revenue | $806.8M |
| Net Income | -$559,017,000 |
| Gross Proft | $749.4M (2024) |
| EBITDA | ($135.4M) (2024) |
| PE Ratio | -4.91 |
| Tax Rate | -0.0% |
| Market Capitalization | $1.8B |
| Total Assets | $1,705,619,000 |
| Ticker | PTCT |
PTC Therapeutics jobs you might like
PTC Therapeutics financing
PTC Therapeutics received early financing of $40.0M on 2001-09-19.
| Series | Round size | Date |
|---|---|---|
| Series D | $40M | 09/2001 |
| Series E | $35M | 01/2004 |
| Series E | $15M | 06/2004 |
| Private Equity | $26.6M | 11/2005 |
| Series F | $10M | 02/2007 |
| Grant | $1M | 12/2009 |
| Series Unknown | $50M | 12/2009 |
| Private Equity | $5M | 12/2011 |
| Private Equity | $30M | 07/2012 |
| Private Equity | $60M | 03/2013 |
| Series Unknown | $4.5M | 05/2013 |
| Post Ipo Debt | $150M | 08/2015 |
| Post Ipo Equity | $140.9M | 04/2020 |
PTC Therapeutics investors
| Investors | Security type |
|---|---|
| China Development Industrial Bank (CDIB) | Series D |
| Delphi Ventures | Series D |
| Bay City Capital | Series D |
| Novo Holdings A | Series D |
| Credit Suisse | Series D |
| HealthCap | Series D |
| Manulife Financial | Series D |
| New Medical Technologies | Series D |
| CDI Bioscience | Series D |
| HBM Healthcare Investments AG | Series E |
| Delphi Ventures | Series E |
| Bay City Capital | Series E |
| Novo Holdings A | Series E |
| Vulcan Capital | Series E |
| Credit Suisse First Boston | Series E |
| HealthCap | Series E |
| POSCO BioVentures | Series E |
| HBM Healthcare Investments AG | Series E |
| Delphi Ventures | Series E |
| Bay City Capital | Series E |
| Novo Holdings A | Series E |
| Vulcan Capital | Series E |
| Credit Suisse First Boston | Series E |
| HealthCap | Series E |
| POSCO BioVentures | Series E |
| HBM Healthcare Investments AG | Private Equity |
| Delphi Ventures | Private Equity |
| Novartis Venture Fund | Private Equity |
| Bay City Capital | Private Equity |
| Birchmere Ventures | Private Equity |
| Novo Holdings A | Private Equity |
| Vulcan Capital | Private Equity |
| Credit Suisse | Private Equity |
| HealthCap | Private Equity |
| Amgen Inc. | Private Equity |
| Delphi Ventures | Series F |
| Bay City Capital | Series F |
| Vulcan Capital | Series F |
| Credit Suisse First Boston | Series F |
| Delphi Ventures | Series Unknown |
| HBM Healthcare Investments AG | Series Unknown |
| Novo Holdings A | Series Unknown |
| Credit Suisse | Series Unknown |
| The Column Group | Series Unknown |
| Wellcome Trust | Private Equity |
| Delphi Ventures | Private Equity |
| HBM Healthcare Investments AG | Private Equity |
| Novo Holdings A | Private Equity |
| Credit Suisse | Private Equity |
| Brookside Capital Inc | Private Equity |
| Delphi Ventures | Private Equity |
| Jennison Associates | Private Equity |
| Novo Holdings A | Private Equity |
| Credit Suisse | Private Equity |
| Longwood Fund | Private Equity |
| Vulcan Capital | Private Equity |
| Adage Capital Management | Private Equity |
PTC Therapeutics competitors
PTC Therapeutics's top competitor, Merck, earned an annual revenue of $64.2B.
PTC Therapeutics's smallest competitor is Trevena with revenue of $3.8M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Alnylam Pharmaceuticals | $81,014 | $2.2B | 1,323 | 1 |
| Vertex Pharmaceuticals | $95,952 | $11.0B | 3,400 | 270 |
| Merck | $90,328 | $64.2B | 74,000 | 1,423 |
| Forest Laboratories | $91,901 | $3.6B | 6,200 | - |
| Intercept Pharmaceuticals | $93,850 | $285.7M | 437 | - |
| Esperion Therapeutics | $75,747 | $332.3M | 218 | 45 |
| Intarcia Therapeutics | $76,606 | $70.0M | 44 | - |
| Exelixis | $108,978 | $2.2B | 484 | 175 |
| Sarepta Therapeutics | $94,985 | $1.9B | 840 | 25 |
| Trevena | $64,889 | $3.8M | 25 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
PTC Therapeutics highest paying jobs
Zippia gives an in-depth look into the details of PTC Therapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about PTC Therapeutics. The employee data is based on information from people who have self-reported their past or current employments at PTC Therapeutics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by PTC Therapeutics. The data presented on this page does not represent the view of PTC Therapeutics and its employees or that of Zippia.
PTC Therapeutics may also be known as or be related to PTC THERAPEUTICS, INC., PTC Therapeutics, PTC Therapeutics Inc, PTC Therapeutics Inc., PTC Therapeutics, Inc. and Ptc Therapeutics, Inc.